Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead ...

Metsera’s obesity drug candidate targeting the amylin hormone showed marked efficacy in an early trial, the company said ...

The following is a summary of “Oral semaglutide for the treatment of obesity: a retrospective real-world study,” published in ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

The European Medicines Agency announced on Friday that its safety committee has concluded that Novo Nordisk’s (NVO) (OTCPK:NONOF) popular weight loss/diabetes therapy semaglutide can cause a side ...

What if the secret to weight loss isn't in a pill, but in your daily routine? That's the question Corewell Health's Lifestyle ...

Long Islanders, doctors and industry experts weigh in on medicines like Ozempic and Wegovy — how they work, what they ...

More Americans are turning to medical weight loss drugs to lose weight. Before you start, you may want to think about speaking with a registered dietitian ...

By pairing semaglutide with one or two experimental antibodies designed to preserve muscle, participants lost less lean body ...